Product Description
Mechanisms of Action: 5-HT2A Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hospices Civils de Lyon
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tourette Syndrome|Rett Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03970239 |
Park-IMPULSE | N/A |
Unknown status |
Parkinson's Disease|Conduct Disorder |
2022-02-13 |
2024-10-16 |
||
2023-506370-13-00 |
69HCL22_0683 | P2 |
Recruiting |
Tourette Syndrome|Rett Syndrome |
2028-10-01 |
2025-05-02 |
Treatments |
|
2019-000340-99 |
2019-000340-99 | P2 |
Completed |
Unknown |
2023-04-26 |